Review Questions Whether Valproate Should Be First-Line Treatment for Acute Mania

New evidence suggests commonly prescribed mood stabilizer may be less effective than lithium and other antipsychotics for treating acute bipolar mania

A growing body of evidence suggests that valproate—one of the most widely prescribed medications for bipolar mania—may not deserve its place at the front of the line.

A comprehensive review published in Psychiatric Times in March 2026 challenges what has become standard practice in many psychiatric offices: reaching for valproate first when a patient presents with acute mania.

The findings raise uncomfortable questions about why a drug with a weaker evidence base continues to dominate prescribing habits when stronger treatment options are available.

The Numbers are Striking Meta-analyses of controlled studies show valproate has a standardized mean difference of just 0.16 versus placebo for acute mania—the smallest effect size among major mood stabilizers and antipsychotics. By comparison, lithium and several second-generation antipsychotics show effect sizes ranging from 0.37 to 0.56, roughly two to three times stronger.

That gap matters. For someone in the grip of a manic episode, the difference between a medication that barely outperforms a placebo and one with a robust treatment effect can mean weeks of avoidable suffering—or a hospitalization that could have been prevented.

A Declining Track Record Valproate earned its FDA approval for bipolar mania in 1994. But subsequent studies told a different story. Of the next four placebo-controlled trials, the effect size diminished with each one. The final two—one in adults and one in adolescents—showed no statistically significant difference from placebo at all.

Despite this, valproate remains a “go-to” drug. While the latest VA/DoD Clinical Practice Guidelines now classify it as a third-line option (behind lithium, antipsychotics, and carbamazepine), prescribing habits have been slow to catch up.

Safety and Side Effects The side effect profile adds to the concern:

Weight Gain: Head-to-head studies show valproate causes more weight gain than lithium, olanzapine, or quetiapine.
Suicidality: The risk of suicidal behaviors is approximately twice as high on anticonvulsants like valproate compared to controls, whereas lithium shows a unique protective effect.
Teratogenicity: For women of childbearing age, the stakes are highest. Roughly 11% of children exposed to valproate in utero develop malformations, compared to 2-3% in the general population.

What are the Alternatives? The evidence points toward several more robust options:

Lithium: Still the gold standard for acute mania, maintenance, and suicide prevention.
Antipsychotics: Quetiapine, olanzapine, and risperidone show high effect sizes.
Newer Tools: The recent FDA approval of Bysanti (milsaperidone) offers a fresh alternative.

The Exception: Mixed Episodes There is one area where valproate may still hold an edge. Patients experiencing mixed episodes—full mania plus three or more symptoms of depression—appear to respond better to valproate than to some alternatives.

The Bottom Line For the majority of patients with classic bipolar mania, the evidence is clear: other medications work better and carry fewer long-term risks.

If you are currently taking valproate, do not stop your medication on your own. Any changes should be made in consultation with your doctor. However, this data provides a vital opening for an honest conversation about whether your treatment plan reflects the best available evidence.

A Note from Liam Ronan: My doctor first gave me 20mg Xanax (for anxiety disorder) to help calm me. It worked to a degree, but did bring me out of my accute and extended manic episode. He also prescribed me 10mg Ambien which helped me get 5 hours of sleep perhaps, but not enough. I had already been on 100-200mg trazodone to help sleep through the night. Admitably, when I was in the throws of mania, I don’t recall my levels of adherence. At the first signs of I’ve been on more medications than I can count. By the time hypomania had moved to full blown mania, he prescribed me Carbamazapine, which gave me a terrible side effect that no one told me about: I was a zombie. I didn’t like the idea of taking an anti-psychotic, because I was not thinking right at this time. In retrospect, I probably did need or lithium or Valporate. Months later, I found Lamotrigine. And a Later I found a psychiatrist who helped me increase my dose and my mania finally started fading.

Sources:

PMC — Overview of Systematic Reviews | American Journal of Psychiatry

See recent or related posts: